Compare RMCO & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMCO | MDXH |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 41.1M |
| IPO Year | N/A | 2021 |
| Metric | RMCO | MDXH |
|---|---|---|
| Price | $2.88 | $0.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 12.8K | ★ 758.2K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $209.10 | $30.78 |
| Revenue Next Year | $133.33 | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $0.45 |
| 52 Week High | $5.00 | $5.33 |
| Indicator | RMCO | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 59.75 | 18.95 |
| Support Level | $2.75 | N/A |
| Resistance Level | $3.06 | $3.79 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 94.23 | 11.12 |
Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.